Government health authorities have criticized Juul for its marketing practices, scolding the company for claiming its products are a safer alternative to cigarettes. The Food and Drug Administration also demanded the company turn over documents about its marketing, nicotine formula and educational programs. (Associated Press)

Former FDA Commissioner Scott Gottlieb said the federal government should regulate cannabis products after 450 cases of a mysterious lung disease linked to vaping marijuana. “We have to have a federal reckoning here,” Gottlieb said on Squawk Box. (CNBC)

The U.S. district court judge in a landmark opioid trial in Ohio has rejected Purdue Pharma’s effort to dismiss claims that its activities caused a public nuisance. Judge Dan Polster also rejected the company’s push to exclude testimony from an economist who said two Ohio counties suffered more than $200 million in damages from 2006 to 2018. (Reuters)

The FDA wants more men included in clinical trials for treatments for breast cancer. Men account for fewer than 1% of breast cancer cases, but the FDA is calling on researchers to add more male patients to studies of breast cancer treatments. (New York Times)

Novartis CEO Vas Narasimhan has vowed to speed up disclosures in future cases of data integrity. The company acknowledged being aware of discrepancies in data submitted to the FDA regarding Zolgensma, but delayed informing regulators until it finished an internal investigation. (Reuters)